BMRN · BioMarin Pharmaceutical Inc.

This 8-K confirms the culmination of a key regulatory milestone in BioMarin’s acquisition of Amicus Therapeutics: receipt of French foreign direct investment clearance on April 23, 2026. The French FDI Clearance is explicitly described as satisfying the final condition to the Merger other than those inherently fulfilled at closing — such as delivery of closing certificates or representations being true as of closing — thereby removing the last known regulatory hurdle. With closing now scheduled for April 27, 2026, investors can anticipate integration planning to accelerate imminently. The transaction, first announced in December 2025, reflects BioMarin’s strategic expansion into lysosomal storage disorders, complementing its existing rare disease portfolio with Amicus’s lead asset, migalastat, and pipeline assets in Fabry disease and other indications. While the filing does not disclose financial terms — including purchase price, financing arrangements, or anticipated synergies — the speed of execution (four months from signing to final clearance) suggests strong regulatory coordination and limited antitrust complexity outside France. Forward-looking statements caution that actual closing remains subject to customary closing conditions, but no material contingencies are identified beyond procedural items. For investors, this represents a high-conviction signal of near-term consolidation in the rare disease biotech sector, with potential implications for R&D prioritization, commercial integration, and future capital allocation decisions by BioMarin.